Chronic Antiepileptic Toxicity: A Review

Epilepsia

Volumn 16, Issue 2, 1975, Pages 319-352

  Reynolds, E H ^a,b  

^a KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b MRC Clinical Research Centre   (United Kingdom)

Author keywords

Antiepilep tic drugs; Chronic toxicity

Indexed keywords

ANTICONVULSIVE AGENT; FOLIC ACID; GLUCOSE;

ADRENAL CORTEX; ADVERSE DRUG REACTION; BRAIN DISEASE; DRUG TOXICITY; GINGIVA HYPERPLASIA; GLUCOSE INTOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; LIVER TOXICITY; LYMPHADENOPATHY; MEGALOBLASTIC ANEMIA; NEUROTOXICITY; OSTEOMALACIA; PERSONALITY DISORDER; POLYNEUROPATHY; REVIEW; SCHIZOPHRENIA; SKIN TOXICITY; SYSTEMIC LUPUS ERYTHEMATOSUS; WOUND HEALING;

ANTICONVULSANTS; BONE DISEASES; COLLAGEN DISEASES; CONNECTIVE TISSUE; ENDOCRINE DISEASES; EPILEPSY; HEMATOLOGIC DISEASES; HEMATOPOIETIC SYSTEM; HUMAN; IMMUNOLOGIC DISEASES; LIVER; MENTAL DISORDERS; METABOLIC DISEASES; NERVOUS SYSTEM; PERIPHERAL NERVOUS SYSTEM DISEASES; SKIN DISEASES; TIME FACTORS;

EID: 0016734130     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1975.tb06062.x     Document Type: Article

References (325)

1. Cerebellar atrophy in epilepsy
2. Drug‐induced lupus syndromes
3. Antinuclear antibodies in patients on anticonvulsant therapy
4. Folic acid and the half‐life of diphenylhydantoin in man
5. Abnormalities in liver function tests during long‐term diphenylhydantoin therapy in epileptic out‐patients
6. Incidence of diphenylhydantoin gingival hyperplasia
7. 6 status in children with convulsions
8. Congenital defects in folate utilization
9. Gingival hyperplasia and Dilantin content of saliva: A pilot study
10. Some studies on the convulsant action of folic acid
11. Influence of folic acid on blood phenytoin levels
12. Anticonvulsant‐induced antinuclear antibodies and lupus‐like disease in children
13. Effects of convulsions and anticonvulsants on blood sugar in rabbits
14. Knochenstrukturv‐eranderungen bei antikonvulsiver Langzeit‐behandlung
15. Crisi tetanica in soggetto trattato con anticonvulsive
16. Motor nerve conduction velocity during diphenylhydantoin intoxication
17. Generalised lympha‐denopathy as a drug reaction to hydantoin
18. Diphenylhydantoin and the release of adrenocorticotropic hormone in the albino rat
19. Idiosyncratic reactions to the antiepileptic drugs
20. Long‐term administration of antiepileptic drugs and the development of rickets
21. Polinevriti da idantoina
22. Boston Collaborative Drug Surveillance Program. Diphenylhydantoin side effects and serum albumin levels
23. Evaluation of folic acid supplements in children taking phenytoin
24. CSF and serum folic acid and protein changes with diphenylhydantoin treatment
25. Studies of 17‐hydroxycorticosteroids. VIII. Adrenocortical function in patients with convulsive disorders
26. Adrenocortical function in epilepsy. I. The role of Cortisol (hydrocortisone) in the mechanism and management of seizures
27. Effect of diphenylhydantoin on proline and hydroxyproline excretion in the rat
28. Ethosuximide (Zarontin) in the treatment of absence (petit mal) seizures
29. The effect of diphenylhydantoin on nerve conduction velocity
30. Serum copper levels and epilepsy
31. Serum concentration of diphenylhydantoin (phenytoin) and phenobarbital and their relation to therapeutic and toxic effects
32. 12 levels to psychosis in epilepsy
33. Ceruloplasmin rise and protein‐bound iodine fall in human serum during diphenylhydantoin (Dilantin) administration
34. Serum folate values in 423 psychiatric patients
35. Associations of subnormal serum folate and vitamin Bi 2 and effects of replacement therapy
36. Inhibition of intestinal calcium transport by diphenylhydantoin in rat duodenum
37. Ľepreuve de change en histidine comme test de carence en acide folique dans les affections nutritionnelles du systeme nerveux
38. 10 delle atrofie cerebellari tardive in epilettici
39. Megaloblastic anaemia due to phenobarbitone. The convulsant action of therapeutic doses of folic acid
40. Transport of folate into cerebrospinal fluid in man
41. Macrocytosis in patients on anticonvulsant drugs
42. Decreased serum free thyroxine concentration in patients treated with diphenylhydantoin
43. Effect of diphenylhydantoin on Cortisol kinetics in humans
44. Latent osteomalacia in epileptic patients on anticonvulsants
45. Incidence of anticonvulsant osteomalacia and effect of vitamin D: Controlled therapeutic trial
46. Anticonvulsant action” of vitamin D in epileptic patients? A controlled pilot study
47. Effects of diphenylhydantoin upon adrenal cortical function in man
48. Gingival hyperplasia and diphenylhydantoin
49. Pharmacological implications of microsomal enzyme induction
50. Effects of diphenylhydantoin (Dilantin) on adrenal cortical function
51. Plasma glucose and insulin responses to oral glucose with chronic diphenylhydantoin therapy
52. Diphenylhydantoin toxic psychosis with associated hyperglycaemia
53. Malabsorption of folic acid due to diphenylhydantoin
54. Organic changes in phenytoin‐intoxi‐cated pigs
55. Effects of diphenylhydantoin and phenobarbital on the hydroxy‐proline contents of skin in pigs
56. Facilitatory and direct excitatory effects of folate and folinate on single neurones of cat cerebral cortex
57. Folic acid deficiency in patients receiving anticonvulsant drugs
58. Altered calcium metabolism due to anticonvulsant drugs
59. Epilepsy and folate deficiency
60. Osteomalacia with long‐term anticonvulsant therapy in epilepsy
61. The influence of folic acid on the action of diphenylhydantoin
62. Population studies in Dupytren's contracture
63. Coarse features in epilepsy as a consequence of anticonvulsant therapy
64. Diphenylhydantoin‐induced hyperglycaemia and impaired insulin release
65. The effect of anticonvulsant therapy upon the absorption of folates
66. Inhibition of antidiuretic hormone secretion by diphenylhydantoin
67. Untoward effects of phenytoin sodium in epilepsy
68. Megaloblastic anaemia associated with anticonvulsant drugs
69. Uber das Auftreten von Osteomala‐zie nach langdauernder antiepileptischer Therapie
70. Phenytoin (Dilantin) intoxication
71. Pyridoxine and infantile myoclonic seizures
72. 2 in anticonvulsant‐induced megaloblastosis
73. Toxicity of DPH and its effect on wound healing in young guinea pigs
74. Osteomalacia accompanying chronic anticonvulsant therapy
75. Inhibition by diphenylhydantoin of folic acid absorption in man
76. Megaloblastic anaemia during primidone therapy
77. Diphenylhydantoin: Toxicity
78. Antiepileptic drugs: Biotransformation, metabolism, and serum half‐life
79. Hyperglycaemic, non‐ketotic coma following administration of Dilantin (diphenylhydantoin)
80. Atrofia del cerebelo y epilepsia
81. Effect of paroxysmal spike‐wave on continuous visual motor performance
82. Folic acid deficiency from anticonvulsant therapy
83. Folic acid in folate‐deficient patients with epilepsy
84. Folic acid in epilepsy
85. Immunological abnormalities and hydantoins
86. Polycythaemia vera following treatment of megaloblastic anaemia with folic acid
87. Study of psychological effects of ethosuximide (Zarontin) on 25 children suffering from petit mal epilepsy
88. Cerebellar degeneration with clinical manifestation in chronic epileptic patients
89. Tryptophan load tests and pyridoxal‐5‐phos‐phate levels in epileptic children. II. Cryptogenic epilepsy
90. Phenobarbital‐induced alterations in vitamin D metabolism
91. Effect of chronic anticonvulsant therapy on serum 25‐hydroxycholecalciferol levels in adults
92. Mysoline: A new drug in the treatment of epilepsy
93. Studies on dexamethasone metabolism in man: Effect of diphenylhydantoin
94. Phenytoin inhibition of parathyroid hormone induced bone resorption in vitro
95. Luminal bei epilepsie
96. Macrocytosis and macrocytic anaemia caused by anticonvulsant drugs
97. Selective concentration of folic acid activity in cerebrospinal fluid
98. Cerebellar lesions after parenteral Dilantin administration
99. Zerebellarer Daurschaden durch vorubergehende Hydan‐toinüberdosierung
100. The epileptogenic action of Na‐folate in the rat
101. Epileptogenic activity of sodium‐folate and the blood‐brain barrier in the rat
102. Über die Veranderung der Leitfunk‐tion peripherer motorischer Nevernfasern durch Diphenylhydantoin
103. Long term anticonvulsant therapy and cerebellar atrophy
104. Relation of abnormal folate metabolism to neuropathy developing during anticonvulsant drug therapy
105. Anticonvulsant drugs and folic acid in young mentally retarded epileptic patients. A study of serum folate, fit frequency and I.Q
106. The resorption of sodium Dilantin produced dermal collagen
107. Dermal chemical response to analogues of Dilantin
108. Diphenylhydantoin: Effects on connective tissue and wound repair
109. The effect of sodium Dilantin administration upon the chemistry of the skin
110. Metabolism of tryptophan in childhood epilepsy
111. Occurrence of skin pigmentation during mesantoin therapy
112. Urinary D‐glucaric acid excretion as a test for hepatic enzyme induction in man
113. Altered calcium metabolism in epileptic children on anticonvulsants
114. Delayed toxicity and serum concentrations of phenytoin
115. Perceptual‐motor behaviour in relation to blood phenobarbitone level: A preliminary report
116. Studies on deficiency and absorption of folates in patients on anticonvulsant drugs
117. Acute effects of diphenylhydantoin in relation to plasma levels. Behavioural and psychological studies
118. Folic acid and anticonvulsive drugs
119. Subnormal serum folatp due to anticonvulsive therapy
120. Absorption and conjugation of metyrapone during diphenylhydantoin therapy: Mechanism of the abnormal response to oral metyrapone
121. Effect of diphenylhydantoin on the metabolism of dexamethasone
122. Diphenylhydantoin‐induced gingival hyperplasia: Its relationship to dose and serum level
123. Effect of diphenylhydantoin on insulin response in the oral glucose tolerance test in children and adolescents
124. Die Wirkung von Diphenylhydantoin auf Impulsiortleitung und Ablauf der Kontraktion in der Skelett‐muskulatur des Menschen
125. Healing qualities of an epilepsy drug
126. Effets psychiques defavorables des medications anticomitiales
127. The treatment of epilepsy with sodium diphenyl‐hydantoinate
128. Experimental investigations of periodontal disease in the ferret and related lesions in man
129. The in‐vitro inhibition of insulin secretion by diphenylhydantoin
130. Diphenylhydantoin intoxication associated with hyperglycemia
131. Subnormal serum folate and macrocytosis associated with anticonvulsant drug therapy
132. Diphenylhydantoin and an insulin‐secreting islet adenoma
133. Phenytoin neurotoxicity and metabolic polymorphism
134. Diphenylhydantoin intoxication and permanent cerebellar dysfunction in epileptic patients
135. Influence of diphenylhydantoin and phenobarbital on intestinal calcium transport in the rat
136. Haemorrhage in the newborn of epileptic mothers
137. Neurological sequelae following Dilantin overdose in a patient and in experimental animals
138. Oral Dilantin in corneal wound healing in the rabbit
139. Movement disorder as a manifestation of diphenylhydantoin intoxication
140. Untersuchungen zum Qalcium‐Stoffwechsel bei Antiepileptischer Therapie
141. The effect of phenobarbital on intestinal calcium transport
142. Chloasnaartige Hyperpigmentier‐ungen nach Behandlung mit Hydantoin‐praparaten
143. Effect of diphenylhydantoin on pituitary‐adrenal interrelations
144. Effect of Dilantin in mice. I. Changes in the lymphoreticular tissue after acute exposure
145. Effect of dilantin in mice. ii. Lymphoreticular tissue atypia and neoplasia after chronic exposure
146. Osteopathien bei antiepileptischer Langzeiltherapie
147. Drugs and enzyme induction
148. Diphenylhydantoin: Interactions with other drugs in man
149. Interactions of antiepileptic drugs
150. Diphenylhydantoin metabolism, blood levels and toxicity
151. Lancet
152. Serial electroencephalographic investigations during psychotic episodes in epileptic patients and during schizophrenic attacks
153. Plasma hydroxyproline in epilepsy
154. The effect of diphenylhydantoin on thyroxine metabolism in man
155. The distribution of plasma phenytoin levels in epileptic patients
156. Ossification disturbances in children under antiepileptic treatment
157. Liver enzyme induction by anticonvulsant drugs, and its relationship to disturbed calcium and folic acid metabolism
158. Coarse facies, calvarial thickening and hyperphosphatemia associated with long‐term anticonvulsant therapy
159. Brain injury, drugs, and environment as causes of mental decay in epilepsy
160. Inhibition of insulin secretion by diphenylhydantoin in the isolated perfused pancreas
161. Diphenylhydantoin: Its use in detecting early insulin secretory defects in patients with mild glucose intolerance
162. Transport characteristics of folates in cerebrospinal fluid: A study using doubly labeled 5‐methyltetrahydrofolate and 5‐formyltetrahydrofolate
163. Diphenylhydantoin activated seizures
164. Serum protein binding of thyroxine and diphenylhydantoin
165. Bone density in patients receiving long‐term anticonvulsant therapy
166. Vitamin D in patients on anticonvulsants
167. Anticonvulsant drugs and vitamin D metabolism
168. Diphenylhydantoin gingival hyperplasia
169. Hypertrichosis occurring in association with Dilantin therapy
170. Study of the effects of diphenylhydantoin sodium on the lungs
171. Pseudodegenerative disease due to diphenylhydantoin intoxication
172. Peripheral neuropathy in long‐term diphenylhydantoin therapy
173. The lack of pulmonary fibrosis in patients receiving diphenylhydantoin
174. Dupytren's contracture and epilepsy
175. Residual cerebellar systems dysfunction and peripheral neuro‐' pathy after diphenylhydantoin therapy
176. Rickets and anticonvulsant therapy in children. A roentgenological investigation
177. Diphenylhydantoin and rickets
178. Diphenylhydantoin effects on human lymphocytes in vitro and in vivo
179. Vitamin D‐depen‐dency rickets in institutionalized, mentally retarded children on long term anticonvulsant therapy, ii. The response to 25‐Hydroxycholecalciferol and to Vitamin D2
180. Effect of diphenylhydantoin on insulin secretion in man
181. Serum folic acid and vitamin Bi 2 levels in anticonvulsant therapy
182. General principles: Biotransformation
183. Die hamatologischen Komplika‐tionen der Epilepsiebehandlung mit Hydan‐toinkorpem
184. Myopathy associated with anticonvulsant osteomalacia
185. An autopsy case of chronic diphenylhydantoin intoxication
186. Folate therapy in epilepsy
187. The metabolism of vitamin D3 in man: The influence of the state of Vitamin D nutrition
188. Folate deficiency after anticonvulsant drugs; an effect of hepatic enzyme induction
189. Choreo‐athetosis and encephalopathy induced by phenytoin
190. Effect of phenytoin on the tryptophan load test
191. Effect of diphenylhydantoin on the metabolism of metyrapone and release of ACTH in man
192. Absorption and distribution of antiepileptic drugs
193. Effect of 5,5′‐diphenylhydantoin on the metabolism of L ‐thyroxine in the rat
194. Abnormal glucose‐tolerance tests in patients treated with sedative drugs
195. Alteraciones de las Ceruloplasmia y el cobre sericos en epilepticos
196. Sodium diphenyl‐hydantoinate in the treatment of convulsive disorders
197. Megaloblastic anaemia in anticonvulsant therapy
198. Ľintoxica‐tion par les hydantoines: Manifestations neurologiques
199. Serum folate deficiency in children receiving anticonvulsant therapy
200. Diphenylhydantoin: Placental transport, fetal localisation, neonatal metabolism, and possible teratogenic effects
201. Studies of paroxysmal EEG phenomena and background EEG in relation to impaired attention
202. Pulmonary changes in hydantoin therapy
203. Effect of diphenylhydantoin on peripheral nerve
204. Neonatal coagulation defect due to anticonvulsant drug treatment in pregnancy
205. Mental deterioration in epilepsy due to folate deficiency
206. A controlled study of folic acid in epilepsy
207. Depression of the serum protein‐bound iodine level by diphenylhydantoin
208. Displacement of thyroxine from human thyroxine‐binding globulin by analogues of hydantoin. Steric aspects of the thyroxine‐binding site
209. Effet des antiepileptiques sur la fonction erythropietique de ľenfant
210. Two cases of rickets during anticonvulsant medication
211. The hyperkinetic syndrome in epileptic children
212. The effect of anticonvulsant drugs on the gingiva. A series of analyses of 1048 patients
213. The neurologic hazards of diphenylhydantoin in childhood
214. Serum concentration of antiepileptic drugs
215. Diphenylhydantoin inhibition of calcitonin secretion in the pig
216. Unrecognised Dilantin intoxication
217. Observations on folate absorption with particular reference to folate polyglutamate and possible inhibitors to its absorption
218. Hyperglycaemia with relative hypoinsulinemia in diphenylhydantoin toxicity
219. Abnormal copper and tryptophan metabolism and chelation therapy in anticonvulsant drug intolerance
220. Dupytren's disease. Its association with abnormal liver function in alcoholism and epilepsy
221. Relationship of serum to red cell folate concentrations in drug treated epileptic patients
222. Severe bradykinesia as a manifestation of toxicity to antiepileptic medications
223. Influence of diphenylhydantoin on spontaneous release of ovulating hormone in the adult rat
224. Osteoporotic fractures secondary to methotrexate therapy of acute leukemia in remission
225. Effects of folic acid on fit frequency and behaviour in epileptics on anticonvulsants
226. Diphenylhydantoin intoxication and cerebrospinal fluid protein
227. Activity of red cell glutamic oxalacetic transaminase in epileptic children under antiepileptic treatment
228. Effects of folic acid on the mental state and fit frequency of drug‐treated epileptic patients
229. Epilepsy and schizophrenia: Relationship and biochemistry
230. Iatrogenic disorders in epilepsy
231. Anticonvulsant drugs, folic acid metabolism, fit frequency and psychiatric illness
232. Diphenylhydantoin: Hematologic aspects of toxicity
233. Anticonvulsant drugs, folate deficiency and metabolic bone disease
234. Anticonvulsants, folic acid and epilepsy
235. Neuropsychiatric aspects of anticonvulsant megaloblastic anaemia
236. 2 metabolism and mental symptoms
237. Relationship between serum and cerebrospinal fluid folate
238. Relationships between serum and cerebrospinal fluid anticonvulsant drug and folic acid concentrations in epileptic patients
239. Anticonvulsant therapy, megaloblastic haemopoeisis and folic acid metabolism
240. Folic acid and anticonvulsants
241. Folate metabolism in epileptic and psychiatric patients
242. Neurological disease associated with folate deficiency
243. Serum anticonvulsant concentrations in epileptic patients with mental symptoms
244. Folic acid in epilepsy
245. Disturbance of calcium metabolism by anticonvulsant drugs
246. Interaction between anticonvulsant drugs and vitamin D
247. Acute effects of phenytoin on serum folate concentrations
248. Chronic hydantoin intoxication: Case report
249. Effect of diphenylhydantoin treatment on the release of corticotrophin in epileptic patients
250. Site of the inhibiting action of diphenylhydantoin on the release of corticotrophin in epileptic patients
251. Differences between epileptic and nonepileptic children with special reference to the tryptophan tolerance test
252. Incidences psychiatriques et psychologiques due traitement par ľethosuccimide chez les epileptiques
253. A propos des accidents neurologiques du traitement de ľepilepsie par les hydantoines
254. Dilantin dementia
255. Hyperglycemia associated with diphenylhydantoin (Dilantin) intoxication
256. Lymphadeno‐pathy induced by anticonvulsant drugs and mimicking clinically and pathologically malignant lymphomas
257. Vitamin‐D‐Stoff‐wechsel und Antiepileptica
258. Intestinal absorption of vitamin D3 in epileptic patients and phenobarbital‐treated rats
259. Calciumstoffwechselstorungen bei antiepileptischer Therapie
260. Osteopathien bei antiepileptischer Damerbehandlung
261. Diphenylhydantoin‐induced cerebellar degeneration
262. Effect of Dilantin sodium analogues on cell proliferation in tissue culture
263. Response of radiated human gingival fibroblast‐like cells to Dilantin sodium in cell culture
264. Effects of Dilantin on the tensile strength of healing wounds
265. Acceleration of gingival wound healing in non‐epileptic patients receiving DPH sodium
266. The effect of phenobar‐bitone induction on vitamin D metabolism
267. Use of sodium Dilantin in the treatment of leg ulcers
268. Effect of Dilantin sodium on healing of experimentally produced fractures in rabbit mandibles
269. and Reynolds EH. Serum immunoglobulins in epilepsy
270. Folate metabolism and the anticonvulsant efficacy of phenobar‐bital
271. Myopathy, osteomalacia and hyperparathyroidism
272. Muscular weakness in osteomalacia and hyperparathyroidism
273. 2 in epileptics with and without mental illness
274. Calcium metabolism during anticonvulsant therapy
275. Drug‐induced dendritic sprouts on Purkinje cells in the adult cerebellum
276. Diphenylhydan‐toin: Proliferating membranes in cerebellum resulting from intoxication
277. Coagulation defects caused by diphenylhy‐dantoin
278. Depression of immunological function in patients treated with phenytoin sodium (sodium diphenylhydan‐toin)
279. Radiological bone changes and hypocalcemia with anticonvulsant therapy in epilepsy
280. Effets psychiatriques defavorables des medications antiepilepti‐ques
281. 2 in patients on anticonvulsants
282. Effects of formyl tetrahydrofolic acid and noradrenaline on the oxygen consumption of rat brain synaptosome‐mitochrondrial preparations
283. Influence of folic acid on excitable tissues
284. Plasma levels and therapeutic effect of 25‐hydroxycholecalciferol in epileptic patients taking anticonvulsant drugs
285. Absence of characteristic reactions in the peridontum and other peripheral tissues of hamsters showing neurophysiologic responses to chronic administration of Dilantin
286. The effects of phenobarbital on bile salts and bilirubin in patients with intrahepatic and extrahepatic cholestasis
287. Ossifikationsstorungen bei anti‐konvulsiver Langzeitbehandlung
288. Diphenylhydantoin: Hematologic aspects of toxicity
289. Clinical and experimental studies on folic acid deficiency due to anticonvulsants. II. Investigations on patients receiving anticonvulsants and experimental study on the effect of diphenylhydantoin on the absorption of folic acid in rats
290. Quelques effets indesirables des medicaments anti‐epilep‐tiques sur les rendements intellectuels
291. Comparative and serial assays of folate metabolism in anticonvulsant‐treated epileptics
292. Rickets precipitated by anticonvulsant drugs
293. Low plasma bilirubin in epileptics on phenobarbitone
294. Drugs effective in convulsive disorders
295. Hyperglycaemia due to phenytoin toxicity
296. Parenchymatous cerebellar degeneration complicating diphenylhydantoin (Dilantin) therapy
297. Parenchymatous cerebellar degeneration with Dilantin intoxication
298. Phenobarbital and the shoulder‐hand syndrome
299. Osteomalacia due to phenytoin sodium
300. Low serum calcium levels in forty mentally subnormal epileptics
301. Influence of phenobarbital and diphenylhydantoin on vitamin D metabolism and calcium retention in rats
302. Cutaneous drug effects in epilepsy
303. Anticonvulsants and folic acid
304. Lactobacillus casei CSF folate activity
305. Interference in the effect of dexamethasone by diphenylhydantoin
306. Effect of diphenylhydantoin on Cortisol metabolism in man
307. Cortisol production in epileptic patients treated with diphenylhydantoin
308. Effects of phenobarbital, phenytoin and anoxia on connective tissue in mice
309. Findings suggestive of systemic lupus erythematosus in subjects on chronic anticonvulsant therapy
310. Relation between the adrenal cortex and the central nervous system
311. Pharmacology and mechanisms of action of diphenylhydantoin
312. Trinuride in the treatment of major epilepsy
313. Sensory and motor nerve conduction velocity in long‐term diphenylhydantoin therapy